The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

Ozempic (semaglutide) and Trulicity (dulaglutide) are prescription drugs used for people with type 2 diabetes and certain other conditions. Both drugs are injected under the skin. Ozempic and ...

Of the 37.1 million patients with type 2 diabetes, 810,390 were new semaglutide users, 326,282 were treated with dulaglutide, 25,936 with exenatide (Byetta, Bydureon), 715,802 with empagliflozin ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Adults with T2D taking semaglutide, other glucagon-like peptide 1 receptor agonists (GLP-1 RAs; dulaglutide and exenatide), or non-GLP-1 RA medications (empagliflozin, sitagliptin, and glipizide) from ...

Adults with type 2 diabetes using semaglutide, dulaglutide (Trulicity, Eli Lilly), exenatide, empagliflozin (Jardiance, Boehringer Ingelheim), sitagliptin (Januvia, Merck) or glipizide from ...

GPs are free to prescribe semaglutide to all eligible patients in line with NICE guidelines after long-term shortages have ...

showing that once-weekly semaglutide significantly reduced HbA1c and body weight in persons with type 2 diabetes when compared to dulaglutide. Additionally, the obesity segment is predicted to ...